Treatment and outcomes of metastatic colorectal cancer patients in public and private hospitals: results from the South Australian Metastatic Colorectal Cancer Registry
- 27 January 2020
- journal article
- research article
- Published by Wiley in Internal Medicine Journal
- Vol. 51 (1) , 69-77
Abstract
Background: Studies have reported significant differences in baseline characteristics and outcomes of metastatic colorectal cancer (mCRC) patients when managed in private versus public hospitals.Aims: To compare disease, treatment and survival outcomes of patients with mCRC in public versus private hospitals in South Australia (SA).Methods: Analysis of prospectively collected data from the SA mCRC Registry. Patterns of care and outcome data according to location of care and socioeconomic status based on Index of Relative Socio‐Economic Advantage and Disadvantage were analysed.Results: A total of 3470 patients’ data was analysed during February 2006–January 2015. The majority (70%) of patients received treatment in public hospitals. Patients in the upper 50% for Index of Relative Socio‐Economic Advantage and Disadvantage score were more likely to receive treatment at a private hospital (41.2% vs 21.56%) compared to P = 0.005). Public patients received less treatment compared to the private patients (odds ratio = 0.48 (0.38–0.61), P = 0.01) and rates of surgical resections were lower in public patients. After adjusting for the covariates, public patients survive 1.33 months (P = 0.025) shorter than private patients with follow‐up time of 5 years. Patients receiving metastasectomy and more than three lines of treatment were shown to have the greatest survival benefit.Conclusion: Public patients have a higher burden of disease and in comparison are less likely to receive systemic therapy and have lower survival than patients treated in private hospitals.Keywords
This publication has 21 references indexed in Scilit:
- Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcomeBMC Medical Research Methodology, 2013
- Improvement in survival of metastatic colorectal cancer: Are the benefits of clinical trials reproduced in population-based studies?European Journal of Cancer, 2013
- Cancer statistics, 2011CA: A Cancer Journal for Clinicians, 2011
- The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubtStatistics in Medicine, 2011
- A 50% higher prevalence of life-shortening chronic conditions among cancer patients with low socioeconomic statusBritish Journal of Cancer, 2010
- Patient Comorbidities and Behaviour Once Diagnosed Are Major Contributors to Disparities in Cancer Health OutcomesJournal of Clinical Oncology, 2010
- Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved ChemotherapyJournal of Clinical Oncology, 2009
- The impact of socioeconomic status on survival after cancer in the United StatesCancer, 2008
- Delay in Treatment of Colorectal Cancer: Multifactorial ProblemWorld Journal of Surgery, 2003
- Delay in the diagnosis and outcome of colorectal cancer:a prospective studyEuropean Journal of Surgical Oncology, 1999